(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Monday reported interim results from the ongoing Phase 2 COURAGE study evaluating semaglutide and trevogrumab with or without garetosmab for the ...

The dozen new drugs, including those furthest along in development from Eli Lilly, Regeneron, Scholar Rock and Veru, target proteins tied to muscle preservation or growth.

In the 106-patient ADEPT study, BP patients treated with 300 mg of Dupixent every two weeks achieved sustained disease remission at a rate five times higher (20%) than the 4% rate recorded for the ...

Regeneron’s strategy relies on two experimental lab-made antibodies, trevogrumab and garetosmab. Both antibodies are linked to separate proteins that play key roles in limiting skeletal muscle ...

Sanofi, Regeneron: ADEPT Study Of Dupixent In Bullous Pemphigoid Meets Endpoints September 11, 2024 — 01:27 am EDT Written by RTTNews.com for RTTNews -> ...

Triple combo therapy cut 30 pounds with just 2 lbs of lean mass lost, showing strong fat-targeting results in the midstage trial. Regeneron inks $80 million deal with Hansoh for Phase 3 obesity ...

Regeneron has promising muscle preservation in obesity treatment, "Trevogrumab," in phase two. Libtayo is Regeneron's PD-1 inhibitor approved for certain skin cancers and is under investigation ...